Tasquinimod Improves Radiographic PFS in mCRPC

This article originally appeared here.
Share this content:
Tasquinimod Improves Radiographic PFS in mCRPC
Tasquinimod Improves Radiographic PFS in mCRPC

THURSDAY, June 16, 2016 (HealthDay News) -- For chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC), tasquinimod is associated with improved radiographic progression-free survival (rPFS), according to a phase III study published online June 13 in the Journal of Clinical Oncology.

Cora Sternberg, M.D., from the San Camillo Forlanini Hospital in Rome, and colleagues conducted a phase III trial involving men with chemotherapy-naive mCRPC and evidence of bone metastases. A total of 1,245 patients were randomized to tasquinimod once per day (832 men) or placebo (413 men) at 241 sites in 37 countries. The primary end point was rPFS per Prostate Cancer Working Group 2 criteria and RECIST 1.1.

The researchers found that the estimated median rPFS by central review was 7.0 and 4.4 months with tasquinimod and placebo, respectively (hazard ratio, 0.64; 95 percent confidence interval, 0.54 to 0.75; P < 0.001). The median overall survival (OS) was 21.3 and 24.0 months with tasquinimod and placebo, respectively (hazard ratio, 1.10; 95 percent confidence interval, 0.94 to 1.28; P = 0.25). More frequent grade ≥3 adverse events were seen with tasquinimod (42.8 versus 33.6 percent), most commonly anemia, fatigue, and cancer pain.

"In chemotherapy-naive men with mCRPC, tasquinimod significantly improved rPFS compared with placebo," the authors write. "However, no OS benefit was observed."

Several authors disclosed financial ties to the biopharmaceutical industry; the study was funded by Active Biotech, the manufacturer of tasquinimod.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Influenza Vaccine 48 Percent Effective Overall

CDC: Influenza Vaccine 48 Percent Effective Overall

More severe H3N2 strain a factor in reduced coverage

D.C. Zika Tests Were Flawed

D.C. Zika Tests Were Flawed

One of the issues with tests was a mathematical error

Experts Warn of Health Threats From Climate Change

Experts Warn of Health Threats From Climate Change

Additional 250,000 deaths/year projected from heat stress, malnutrition, infectious diseases

is free, fast, and customized just for you!

Already a member?

Sign In Now »